Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 18Myelodysplastic Syndromes 4Leukemia, Myeloid 2Carcinoma, Non-Small-Cell Lung 2Targeted Therapy 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 55fludarabine 29Methotrexate 25blinatumomab 22Dexamethasone 22Cytarabine 21Vincristine 20venetoclax 18fludarabine phosphate 15Specimen Handling 15Whole-Body Irradiation 13Stem Cell Transplantation 11Biopsy 11Tacrolimus 10Prednisone 10Mycophenolic Acid 10Mercaptopurine 10Daunorubicin 10Thiotepa 9Rituximab 9Melphalan 9Immunotherapy, Adoptive 9Doxorubicin 8pegaspargase 7Magnetic Resonance Spectroscopy 7Inotuzumab Ozogamicin 7Granulocyte Colony-Stimulating Factor 7Cyclosporine 7Calcium Dobesilate 7ponatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × gilteritinib × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡